Israel Active

Israel’s Teva has launched, in the USA, a generic alternative to Exforge (amlodopine and valsartan) tablets used to treat hypertension (high blood pressure). }

Professor Marta Weinstock-Rosin – inventor of Exelon for treating Alzheimer’s – says that the end is in sight for the debilitating disease and others like it. Dr Weinstock-Rosin lit one of the ceremonial torches at this year’s Israeli Independence Day ceremony.

Israel’s Rosetta Genomics has received a US patent for its microRNA-based test for the primary tumor type in primary and metastatic (secondary) cancer. By identifying the origin of the tumor, physicians can select the best treatment options for the patient.

In a study of 484 people (99 with stomach cancer), Israel’s NaNose breath detector gave an 80% accurate diagnosis - matching far more expensive, slower and invasive alternatives. NaNose (developed by Technion’s Dr Hossam Haick) also detected pre-cancerous growths that needed attention.

Israel Technion’s Nobel laureate Aaron Ciechanover is in the news for the second week in a row. His recent findings form the basis of a joint project to develop cancer treatments with India’s Sun Pharma.

I featured the amazing work of Tel Aviv University’s Professor Dan Peer in my newsletter. But I thought that you’d like to hear the story from the Professor direct.

Israel’s Kamada has been allowed a patent in Canada for the large-scale production of Alpha-1 Proteinase Inhibitor. The process is key to Kamada’s treatments for alpha-1 antitrypsin (AAT) deficient patients suffering from type-1 diabetes and pulmonary diseases, amongst others.

Medical researchers at Hadassah Medical School in Jerusalem studying the effects of liver transplants in mice, found that in 96% of older, pregnant rodents, the liver regenerated within two days. This compared with 82% of young, non-pregnant mice and 46% of older, non-pregnant ones.

Israel’s Timocco makes motor skills games for developmentally disabled and autistic children. It is now locating its US HQ in Akron Ohio and is working with Akron Children's Hospital, Cleveland Clinic and University Hospitals to introduce the software.

Israel’s Ninox Medical has raised $10 million to fund its development of a new device for the treatment of Obstructive Sleep Apnea (OSA). It is designed to be effective, comfortable to use, and without the side effects typical of other treatment devices.